NCT07297212 2026-03-12
A Clinical Trial Testing the Safety of the Investigational Drug Pumitamig (BNT327) and How Well it Works in Patients With Recurrent Glioblastoma
BioNTech SE
Phase 2 Recruiting
Clinical Trials
101 trialsNCT01068782 2026-02-25
Multiple Doses and Regimens of Cabozantinib in Subjects With Grade IV Astrocytic Tumors in First or Second Relapse
Exelixis
Phase 2 Terminated
NCT06805305 2026-02-23
DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM)
Diakonos Oncology Corporation
Phase 2 Recruiting
NCT06061809 2026-02-12
N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma
ImmunityBio, Inc.
Phase 2 Recruiting
NCT04485949 2026-02-10
A Phase 2b Clinical Study With a Combination Immunotherapy in Newly Diagnosed Patients With Glioblastoma
Imvax
Phase 2 Active not recruiting
NCT07225621 2026-02-05
Adjuvant Temozolomide ± 5-Aminolevulinic Acid + Low Intensity Diffuse Ultrasound Sonodynamic Therapy System for Newly Diagnosed Glioblastoma
Alpheus Medical, Inc.
Phase 2 Recruiting
NCT04752813 2026-01-26
A Study of BPM31510 With Vitamin K1 in Subjects With Newly Diagnosed Glioblastoma (GB)
BPGbio
Phase 2 Active not recruiting
NCT07356973 2026-01-26
OPTICAL
CRISM Therapeutics LTD
Phase 2 Not yet recruiting
NCT07365280 2026-01-26
Neoantigen-Pulsed Autologous Dendritic Cell Vaccine Combined With Temozolomide for Newly Diagnosed Glioblastoma
ZSky Biotech Inc
Phase 2 Not yet recruiting
NCT05267106 2025-12-30
FIGHT-209
Incyte Corporation
Phase 2 Terminated
NCT06359379 2025-12-18
Ropidoxuridine as a Radiosensitizer in Newly Diagnosed IDH-Wildtype Glioblastoma With Unmethylated MGMT Promoter
Shuttle Pharmaceuticals, Inc.
Phase 2 Terminated
NCT03862430 2025-10-09
RESTORE
NuvOx LLC
Phase 2 Active not recruiting
NCT03050736 2025-09-04
Safety Study of VAL-083 and Radiotherapy in Patients With Newly Diagnosed GBM Having Unmethylated MGMT Expression
Kintara Therapeutics, Inc.
Phase 2 Completed
NCT02717962 2025-08-29
Study of VAL-083 in Patients With MGMT Unmethylated, Bevacizumab-naive Glioblastoma in the Adjuvant or Recurrent Setting
Kintara Therapeutics, Inc.
Phase 2 Completed
NCT04587830 2025-08-26
GBM
Polaris Group
Phase 2 Active not recruiting
NCT07138001 2025-08-22
Phase 2 Clinical Trial of KH617
Chengdu Kanghong Pharmaceutical Group Co., Ltd.
Phase 2 Not yet recruiting
NCT02986178 2025-07-11
Lerapolturev in Recurrent Malignant Glioma
Istari Oncology, Inc.
Phase 2 Completed
NCT05563272 2025-07-10
STARBURST
Telix Pharmaceuticals (Innovations) Pty Limited
Phase 2 Terminated
NCT03175224 2025-06-27
SPARTA
Apollomics Inc.
Phase 2 Recruiting
NCT04479241 2025-06-05
LUMINOS-101: Lerapolturev (PVSRIPO) and Pembrolizumab in Patients With Recurrent Glioblastoma
Istari Oncology, Inc.
Phase 2 Completed
NCT03897491 2025-05-14
PD L 506 for Stereotactic Interstitial Photodynamic Therapy of Newly Diagnosed Supratentorial IDH Wild-type Glioblastoma
photonamic GmbH & Co. KG
Phase 2 Active not recruiting
NCT06598787 2025-05-07
A Study of BL-B01D1 in Patients With Recurrent Glioblastoma
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2 Recruiting
NCT04762069 2025-05-04
A Study of Berubicin in Adult Subjects With Recurrent Glioblastoma Multiforme
CNS Pharmaceuticals, Inc.
Phase 2 Active not recruiting
NCT04704154 2025-04-18
A Trial to Learn Whether Regorafenib in Combination With Nivolumab Can Improve Tumor Responses and How Safe it is for Participants With Solid Tumors
Bayer
Phase 2 Completed
NCT03522298 2025-03-24
Safety, Pharmacokinetics and Efficacy of Paxalisib (GDC-0084) in Newly-diagnosed Glioblastoma
Kazia Therapeutics Limited
Phase 2 Completed
NCT01903330 2025-03-05
ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma Multiforme
Epitopoietic Research Corporation
Phase 2 Active not recruiting
NCT06161974 2025-02-21
Study of Olutasidenib and Temozolomide in HGG
Rigel Pharmaceuticals
Phase 2 Recruiting
NCT06336291 2025-01-24
GLIOSTELLA
Philogen S.p.A.
Phase 2 Recruiting
NCT02525692 2024-12-24
Oral ONC201 in Adult Recurrent Glioblastoma
Jazz Pharmaceuticals
Phase 2 Terminated
NCT06595186 2024-09-19
JK-1201I Combined with Adjuvant Temozolomide in Patients with Newly Diagnosed Glioblastoma Multiforme (GBM)
JenKem Technology Co., Ltd.
Phase 2 Recruiting
NCT05986851 2024-09-05
Azeliragon in MGMT Unmethylated Glioblastoma
Cantex Pharmaceuticals
Phase 2 Active not recruiting
NCT04492163 2024-08-16
Open-Label Pilot Study of OPTUNE® With High Density Transducer Arrays for the Treatment of Recurrent GBM
NovoCure Ltd.
Phase 2 Completed
NCT06353360 2024-08-09
TTField in Combination With Temozolomide and Tislelizumab in The Treatment of Newly Diagnosed Glioblastoma.
Jiangsu Healthy Life Innovation Medical Technology Co., Ltd
Phase 2 Recruiting
NCT02014844 2024-05-29
Phase 2 Study to Investigate the Efficacy and Safety of Aldoxorubicin in Subjects With Glioblastoma
ImmunityBio, Inc.
Phase 2 Completed
NCT02067156 2024-05-21
Efficacy, Safety and CNS Exposure of G-202 (Mipsagargin) in Patients With Recurrent or Progressive Glioblastoma
GenSpera, Inc.
Phase 2 Completed
NCT04681677 2024-04-26
IORT
Xoft, Inc.
Phase 2 Terminated
NCT00589875 2024-04-03
BrTK02
Candel Therapeutics, Inc.
Phase 2 Completed
NCT02684058 2023-12-13
Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors
Novartis
Phase 2 Completed
NCT01290692 2023-07-03
Study To Test the Safety and Efficacy of TVI-Brain-1 As A Treatment for Recurrent Grade IV Glioma
TVAX Biomedical
Phase 2 Completed
NCT01986348 2023-01-26
KING
Karyopharm Therapeutics Inc
Phase 2 Terminated
NCT02858895 2022-10-24
Convection-Enhanced Delivery (CED) of MDNA55 in Adults With Recurrent or Progressive Glioblastoma
Medicenna Therapeutics, Inc.
Phase 2 Completed
NCT01587144 2021-10-19
Safety and Efficacy Study of Lucanthone When Used in Combination With Temozolomide(TMZ) and Radiation to Treat Glioblastoma Multiforme(GBM)
Spectrum Pharmaceuticals, Inc
Phase 2 Terminated
NCT02844439 2021-09-22
Study of Tesevatinib Monotherapy in Patients With Recurrent Glioblastoma
Kadmon Corporation, LLC
Phase 2 Completed
NCT03034135 2021-09-13
Safety, Tolerability and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma
Cantex Pharmaceuticals
Phase 2 Completed
NCT02798406 2021-07-15
CAPTIVE
DNAtrix, Inc.
Phase 2 Completed
NCT04874506 2021-05-05
MBM-02 (Tempol) for the Treatment of Glioblastoma Multiforme (GBM)
Matrix Biomed, Inc.
Phase 2 Unknown
NCT02340156 2021-03-03
Phase II Study of Combined Temozolomide and SGT-53 for Treatment of Recurrent Glioblastoma
SynerGene Therapeutics, Inc.
Phase 2 Terminated
NCT03033524 2021-01-27
Trial to Evaluate the Safety of TTAC-0001(Tanibirumab) in Recurrent Glioblastoma
PharmAbcine
Phase 2 Completed
NCT02296476 2021-01-26
MK-8628-002
Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 2 Terminated
NCT00586508 2020-09-24
Trial of Enzastaurin and Bevacizumab in Participants With Recurrent Malignant Gliomas
Eli Lilly and Company
Phase 2 Completed